ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
September 02 2014 - 4:15PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the Company will
participate in the Morgan Stanley Global Healthcare Conference.
Consistent with the Conference’s format, ImmunoGen President and
CEO Daniel Junius will discuss the Company in a moderated question
and answer session that will be webcast beginning at 9:55am ET on
September 8, 2014.
This webcast will be accessible live through the “Investor
Information” section of the Company’s website, www.immunogen.com; a
replay will be available at the same location for approximately a
week.
The Company also will be participating in one-on-one meetings at
the 9th Annual Citi Biotech Conference September 4, 2014 in Boston,
MA.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024